Press release
ER+ Breast Cancer Pipeline Analysis - Clinical Trials, Patent, Designation and Collaboration
Explore report sample at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample
Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of their drug candidates in ER+ breast cancer. The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process by effectively comparing the molecular profiles of successful drugs, failed drugs, and classical toxins.
The research finds that different companies have collaborated for the development of ER+ breast cancer. In January 2016, Radius Health, Inc. entered in a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901 with LEE011 for advanced breast cancer.
Browse Report at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis
Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., and others.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ER+ Breast Cancer Pipeline Analysis - Clinical Trials, Patent, Designation and Collaboration here
News-ID: 1209114 • Views: …
More Releases from P&S Intelligence - Pharmaceuticals
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development.
CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.
Download report sample at: http://bit.ly/2eqiPu5
**Various collaborations for CDK inhibitors drug development
Eli Lilly…
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample
Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the…
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development.
As per the findings of the research, most of the drug candidates are being developed to be administered by oral route.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample
Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,…
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample
The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.…
More Releases for ER+
100G ER vs HTF 400G Coherent Solution: Cost-Effective ER for Short Links, 400G f …
As data centers expand exponentially and cloud-based traffic surges to unprecedented levels, network architects face a persistent, high-stakes challenge: how to scale bandwidth efficiently without compromising on reliability or incurring prohibitive capital expenditures. Amidst this backdrop of relentless digital transformation, network operators are increasingly turning to advanced optical solutions to bridge the gap between short-reach efficiency and long-haul capacity. As a trusted High Quality 100G ER Manufacturer, HTF has emerged…
ER+/HER2- Breast Cancer Clinical Trial Pipeline Analysis: 75+ Key Companies Shap …
DelveInsight's ER+/HER2- Breast Cancer Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline ER+/HER2- Breast Cancer therapies in various stages of clinical development. The report provides insights into 75+ companies and 80+ pipeline drugs in the ER+/HER2- Breast Cancer pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.
Key takeaways from the ER+/HER2- Breast Cancer Clinical Trial Landscape Report
• DelveInsight's ER+/HER2- Breast Cancer…
Texas miscarriage case tests federal ER care rules
AUSTIN, Texas - A Texas woman says two Round Rock hospitals turned her away while she was actively miscarrying at about seven weeks pregnant. Now her federal complaints against both facilities are putting the country's emergency care law to a real test in an abortion-ban state.
The complaints, filed by Lynn Callaway against Baylor Scott & White Medical Center in Round Rock and St. David's Round Rock Medical Center, invoke the…
Optical Brightener ER-I and ER-II Market Size Unveiled: Trends and Projections
The global Optical Brightener ER-I and ER-II market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Optical Brightener ER-I and ER-II market. For instance, the market dynamics section digs deep into the drivers, restraints,…
Optical Brightener ER-I and ER-II Market by Key Players,Competitive landscape an …
LOS ANGELES, United States: The global Optical Brightener ER-I and ER-II market is analyzed in quite some detail in the report with a strong focus on the competitive landscape, segmentation, market dynamics, and regional market expansion. The report includes a thorough assessment of the business of key players operating in the global Optical Brightener ER-I and ER-II market. With deeper qualitative and quantitative analysis of the global Optical Brightener ER-I and…
ER Wagner adding 600-ton Servo Punch Press
Milwaukee-based ER Wagner announced it will have a new 600-ton Servo Punch Press available for production in late 2017, greatly increasing ER Wagner’s metal stamping capabilities.
The Nidec Minster Corporation machine, which will be a part of ER Wagner’s new 157,000-square-foot corporate headquarters and state of the art manufacturing facility currently under construction in the Village of Menomonee Falls, Wis., is latest technology in metal stamping, giving the company the ability…
